The challenges and trends of cell & gene therapies
Drug Discovery World
SEPTEMBER 6, 2022
The fact that these benefits “may not be attainable with small molecules or even simpler biologics, as well as long periods of market exclusivity,” Scharenberg says, means that “more complicated compounds are harder to copy and require more investment to compete with making them strong continued investment targets.” .
130 
Let's personalize your content